Blood Testing Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Blood Testing Market Trends and Insights

Rising Chronic-Disease Burden Fueling Routine & Preventive Blood Panels

Cardiovascular disease, diabetes, and chronic kidney disease affect 1.5 billion people and prompt recurring lipid, hemoglobin A1c, and creatinine testing in annual checkups ^{[2]U.S. Preventive Services Task Force, “Statin Use for the Primary Prevention of Cardiovascular Disease,” USPSTF.org}. The 2024 USPSTF update expanded lipid-panel eligibility to every adult 40-75 years, widening U.S. screening by 20 million lives. Diabetes prevalence hit 537 million adults in 2024 and could reach 783 million by 2045, locking in annual glucose and A1c demand. These routine panels stabilize laboratory volumes even when discretionary testing softens, although tighter bundled-payment contracts now cap margins, prompting more reliance on high-throughput automation.

Rapid Automation & Point-of-Care Analyzer Innovation

FDA clearance of Beckman Coulter’s DxC 500i in March 2025 delivered a 400-test-per-hour platform sized for community hospitals. Abbott gained January 2025 clearance for a high-sensitivity troponin I assay on its handheld i-STAT, enabling 15-minute myocardial-infarction rule-out at the bedside. Sysmex secured CLIA-waived status for its XW-100 hematology analyzer, allowing physician offices to run complete blood counts without a technologist. While POC devices accelerate care, reagent costs run 40-60% higher than central-lab equivalents, challenging cost-sensitive sites.

Government-Funded Screening & Early-Diagnosis Programs

China’s Healthy China 2030 mandates annual exams for 400 million urban workers, propelling double-digit domestic analyzer shipments. India’s Ayushman Bharat program applies national reimbursements to routine panels for 550 million beneficiaries but settles claims in 90-120 days, pressuring small-lab liquidity. Saudi Arabia earmarked USD 64 billion under Vision 2030 for diagnostic hubs capable of 50,000 daily samples. State contracts ensure baseline volumes yet impose price ceilings that favor vertically integrated suppliers.

Lab Reflex-Testing Algorithms Reducing Reagent Waste

A 2024 academic-medical-center study showed automated reflex protocols cut repeat complete blood counts 15%, saving USD 180,000 annually. Vendors now embed configurable rule sets into middleware, but adoption clusters in health systems with dedicated informatics teams. Smaller laboratories lacking IT depth still rely on manual reviews, escalating overtime costs.

Stringent Multi-Region Regulatory Approvals

EU-IVDR reclassified thousands of assays, yet only four notified bodies were designated by end-2024, creating approval bottlenecks and shifting R&D budgets toward high-volume panels. FDA’s May 2024 LDT rule now imposes USD 500,000–2 million validation costs per analyte and 12–24-month timelines, raising barriers for hospital-developed tests. China’s NMPA demands multi-center trials enrolling 200–500 patients, stretching approvals to 30 months. 

High Capex & Consumable Costs for Next-Gen Analyzers

Mid-throughput chemistry systems list at USD 100,000–250,000, while full laboratory automation tops USD 2–5 million, restricting adoption to centers running more than 500,000 tests a year. Reagent-rental contracts shift costs from capex to operating budgets but lock institutions into proprietary chemistries 15–25% above open channels and levy steep early-termination penalties.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Test Type: Infectious-Disease Serology Outpaces Glucose Amid WHO Targets

Infectious-disease serology is projected to post the fastest 8.12% CAGR through 2031 as the WHO pushes 90% hepatitis C diagnosis by 2030 and rapid HIV self-tests gain approval across sub-Saharan Africa. Conversely, glucose assays still held the largest blood testing market share at 29.5% in 2025, supported by 537 million individuals with diabetes. The arrival of over-the-counter continuous glucose monitors, including Dexcom’s Stelo cleared in March 2024, will gradually divert insulin-treated patients away from episodic finger-stick testing^{[3]Dexcom, “Stelo OTC Continuous Glucose Monitor,” FDA.gov}. Lipid panels benefit from 2024 USPSTF guidelines recommending five-year screening intervals, yet retail pharmacy offerings fragment demand. PSA volumes soften as shared-decision guidelines curb annual screening, while BUN and creatinine remain stable due to chronic kidney disease prevalence. TSH and vitamin D utilization face payer scrutiny, trimming low-yield preventive orders, whereas hs-CRP retains a niche in cardiology risk stratification. 

Demand diversity underscores a structural pivot from single-analyte orders to algorithm-guided panels that optimize reagent spend and clinical value. Laboratories that bundle serology, glucose, and lipid assays into preventive-care panels achieve higher throughput and amortize analyzer investments over more billable units. As the blood testing market size for infectious-disease serology climbs, platform vendors that broaden antigen libraries and develop multiplex rapid cards will seize share in public-health tenders. Meanwhile, growth in self-monitoring technologies shifts revenue from central labs to retail channels, signaling a gradual tilt in the blood testing market toward decentralized ecosystems.

By Product: Consumables Dominate, Instruments Accelerate

Consumables represented 55.4% of 2025 revenue, consistent with laboratories’ recurring reagent spend and the ubiquity of BD Vacutainer tubes, which hold an estimated significant global share. Shrinking fee schedules drive laboratories to negotiate high-volume reagent contracts and adopt reflex logic that trims low-yield follow-ons. Yet instruments are set for a 7.21% CAGR through 2031 as facilities replace aging analyzers with integrated chemistry-immunoassay platforms that automate pre-analytic sorting and barcode verification. Such upgrades lower error rates, shorten turnaround, and alleviate technologist shortages. 

Capital budgets favor analyzers that run open channels and support middleware interoperability. The blood testing market size for instruments further expands as point-of-care devices penetrate ambulatory and emergency settings, despite higher per-test reagent costs. Total laboratory automation remains a premium niche but gains traction among academic centers processing more than 1 million annual tests, where 30–40% labor savings justify USD 2–5 million outlays. Overall, suppliers that bundle instrument placements with reagent-rental models lock in multi-year consumable cash flows, reinforcing consumables’ revenue dominance even as instrument volumes rise.

By Technology: Molecular Diagnostics Dominates, Immunoassay Accelerates

Molecular diagnostics generated 45.4% of the blood testing market share in 2025, illustrating how the blood testing market size is shifting toward genomic-level insight that extends well beyond traditional PCR respiratory panels. Liquid-biopsy assays that profile circulating tumor DNA now allow oncologists to track minimal residual disease from a single tube of blood, transforming the sample from a metabolic snapshot into a continuous genomic surveillance tool. Cepheid’s GeneXpert processed 23 million test cartridges in 2024, with tuberculosis and HIV viral-load panels making up 60% of volume in sub-Saharan Africa and South Asia where point-of-care systems bypass cold-chain limits and skilled-technologist shortages. 

In the United States, Abbott’s ID NOW rapid PCR network reached 18,000 physician offices and urgent-care clinics by 2024, delivering influenza and strep results in 13 minutes and cutting unnecessary antibiotic use by roughly one-quarter. Immunoassay technology, led by high-sensitivity troponin I and expanding thyroid, fertility, and tumor-marker menus, is projected to advance at a 7.44% CAGR to 2031, the fastest pace among technologies as emergency departments compress myocardial-infarction rule-out protocols from three hours to one hour and outpatient wellness programs monetize consumer demand for hormone and cancer-risk insight.

By End User: Hospitals Narrow the Gap with Diagnostics Laboratories

Diagnostics laboratories accounted for 57.5% of 2025 spending as Quest Diagnostics, LabCorp, and Sonic Healthcare centralize routine panels and esoteric tests. Quest alone handled 165 million requisitions in 2024 through 2,200 sites. Hospital laboratories, however, are gaining ground with a 7.69% CAGR to 2031. Emergency-department protocols relying on high-sensitivity troponin, lactate, and blood-gas POC analyzers shrink door-to-decision times from hours to minutes, reducing admissions and boosting bed turnover. 

Hospitals also monetize outpatient phlebotomy clinics and capture send-out leakage by insourcing high-volume chemistry and immunoassay panels as analyzer footprints shrink. Meanwhile, thousands of physician offices, urgent-care sites, and retail pharmacies adopt CLIA-waived devices, fragmenting low-volume testing. Although this “other” segment grows appreciably, its dispersed nature yields limited bargaining power, keeping reagent costs elevated. Over the forecast, hospital consolidation and the deployment of middleware that routes tests dynamically between in-house labs and reference partners will rebalance volumes across segments, reshaping competitive dynamics in the blood testing market.

Geography Analysis

North America held 43.6% of global 2025 revenue, propelled by Medicare coverage for preventive panels and the outsized scale of Quest Diagnostics and LabCorp. U.S. laboratories processed 14 billion tests in 2024 for USD 85 billion but face Clinical Laboratory Fee Schedule cuts averaging 8% on 20 high-volume assays, compressing margins. A workforce deficit looms: 70% of labs reported staffing shortages in 2023, and BLS projects just 11% technologist employment growth through 2033, below retirement-replacement needs. Canada centralizes routine testing into provincial hubs, saving cost but extending outpatient turnaround to 24-48 hours. 

Asia-Pacific is the fastest-growing region at an 8.54% CAGR. China’s Healthy China 2030 policy mandates annual exams for 400 million workers, stimulating demand for Mindray, Autobio, and Maccura analyzers priced 20–30% below multinationals. India’s Ayushman Bharat covers 550 million lives, yet 90-day claim lags strain small labs. Japan’s super-aged population fuels lipid and kidney-function testing, but government price ceilings trimmed lab reimbursement by 5–7% in 2024, motivating automation investment. 

Europe balances IVDR transition hurdles with budget caps that restrict spending growth to 1–2% annually. Germany’s 8,000 lab sites consolidated rapidly after a 6% fee cut in 2024, while the U.K. experienced a three-week service disruption in June 2024 when a ransomware attack hit Synnovis, prompting NHS cybersecurity mandates. France’s price-scheduled lab networks invest heavily in automation to maintain 8–12% margins. Gulf Cooperation Council states allocate oil-backed budgets to diagnostic hubs—Saudi Arabia alone earmarked USD 64 billion whereas sub-Saharan Africa relies heavily on donor programs for HIV and malaria testing, leaving the blood testing industry underpenetrated by commercial labs. South America’s middle-class expansion lifts demand, but currency volatility and inconsistent regulations deter multinationals, enabling regional chains such as Dasa and Chopo to dominate through localized cash-pay models.

Regulatory Landscape

Regulatory oversight for blood testing is tightening around high-risk IVDs and digital decision support, with notable regional divergence. In the European Union, IVDR implementation continues to add external scrutiny for Class D devices through EU Reference Laboratories (EURLs), which began independent performance verification and batch testing for initial Class D categories from October 1, 2024. Additional EURL verification requirements took effect on May 1, 2026 under Commission Implementing Regulation (EU) 2025/2526 for certain parasite infection markers and blood grouping markers, increasing documentation and verification work for manufacturers supplying transfusion-related and infectious disease assays.

In the United States, FDA device quality and listing requirements remain a central compliance anchor for IVD manufacturers, alongside the Quality Management System Regulation (QMSR), which became effective February 2, 2026 and aligns device quality requirements more closely with ISO 13485 concepts. The FDA also set May 6, 2026 as a compliance milestone for establishment registration and device listing requirements for most IVDs manufactured by laboratories. In Great Britain, MHRA guidance and the UK Government consultation on Common Specifications for Class D IVDs point to continued alignment efforts for high-risk assays, including proposals to amend the UK MDR 2002 and remove the Coronavirus Test Device Approvals (CTDA) process as the market transitions away from pandemic-era pathways.

Market Opportunities and Future Outlook

Regulatory-driven modernization and acute-care turnaround-time demands are expanding whitespace for automated sample-to-answer systems in high-volume hospital and reference lab workflows. A near-term commercialization proof point is FDA 510(k) clearance activity in 2026 for blood-testing systems and assays that broaden routine and specialty menus, including the BD BACTEC FXI Culture System cleared in June 2026 to automate vial loading and detection for bloodstream infection diagnostics and improve time-to-detection versus prior models. That outcome supports purchasing strategies that favor standardized automation to manage staffing constraints and to reduce manual steps in microbiology and critical-care pathways.

Opportunities are also emerging around algorithm-enabled and decentralized blood testing workflows that connect instruments, middleware, and clinical decision support. Roche's May 2026 launch of the Liver Disease Panel with a certified LiverPRO algorithm underscores a shift from single-analyte reporting toward integrated biomarker-plus-software offerings deployable across routine chemistry and immunoassay footprints. In parallel, device and microfluidics research momentum in centrifuge-free plasma separation and compact point-of-care sample processing is reinforcing product roadmaps aimed at moving more testing into emergency departments, physician offices, and outpatient settings where CLIA-waived and rapid systems reduce reliance on central laboratory capacity.